Milk derived colloid as a novel drug delivery carrier for breast cancer

Abstract Graphene oxide has covalently modified by chito oligosaccharides and γ-polyglutamic acid to form GO-CO-γ-PGA, which exhibits excellent performance as a drug delivery carrier, but this carrier did not have the ability to actively target. In this study, the targeting property of breast cancer tumor cell exosomes was exploited to give GO-CO-γ-PGA the ability to target breast tumor cells (MDA-MB-231), and the drug mitoxantrone (MIT) was loaded to finally form EXO-GO-CO-γ-PGA-MIT with a loading capacity of 1.39 mg/mg. The pH response of EXO-GO-CO-γ-PGA showed a maximum cumulative release rate of 56.59% (pH 5.0) and 6.73% (pH 7.4) for MIT at different pH conditions. pH 7.4). In vitro cellular assays showed that EXO-GO-CO-γ-PGA-MIT was more potent in killing MDA-MB-231 cells due to its targeting ability and had a significantly higher pro-apoptotic capacity compared to GO-CO-γ-PGA-MIT. The results showed that this bionic nano-intelligent drug delivery system has good drug slow release function, can increase the local drug concentration of tumor and enhance the pro-apoptotic ability of MIT, so this newly synthesized bionic drug delivery carriers (EXO-GO-CO-γ-PGA-MIT) has potential application in breast cancer treatment.

Download Full-text

Polymeric Micelle of a Gelatin-Oleylamine Conjugate: A Prominent Drug Delivery Carrier for Treating Triple Negative Breast Cancer Cells

ACS Applied Bio Materials ◽

10.1021/acsabm.8b00526 ◽

2018 ◽

Vol 1 (5) ◽

pp. 1725-1734 ◽

Cited By ~ 7

Author(s):

Iruthayapandi Selestin Raja ◽

Ramar Thangam ◽

Nishter Nishad Fathima

Keyword(s):

Breast Cancer ◽

Drug Delivery ◽

Cancer Cells ◽

Triple Negative Breast Cancer ◽

Breast Cancer Cells ◽

Triple Negative ◽

Polymeric Micelle ◽

Drug Delivery Carrier

Download Full-text

Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control

Current Drug Delivery ◽

10.2174/1567201816666190201144815 ◽

2019 ◽

Vol 16 (5) ◽

pp. 400-429 ◽

Cited By ~ 11

Author(s):

Afzal Hussain ◽

Sima Singh ◽

Sabya Sachi Das ◽

Keshireddy Anjireddy ◽

Subramanian Karpagam ◽

...

Keyword(s):

Drug Delivery ◽

Patient Compliance ◽

Health Concern ◽

Therapeutic Effects ◽

Drug Delivery Carrier ◽

Therapeutic Outcomes ◽

Poor Patient Compliance ◽

General Aspects ◽

High Level ◽

Novel Drug

In spite of advances in tuberculosis (TB) chemotherapy, TB is still airborne deadly disorder as a major issue of health concern worldwide today. Extensive researches have been focused to develop novel drug delivery systems to shorten the lengthy therapy approaches, prevention of relapses, reducing dose-related toxicities and to rectify technologically related drawbacks of anti-tubercular drugs. Moreover, the rapid emergence of drug resistance, poor patient compliance due to negative therapeutic outcomes and intracellular survival of Mycobacterium highlighted to develop carrier with optimum effectiveness of the anti-tubercular drugs. This could be achieved by targeting and concentrating the drug on the infection reservoir of Mycobacterium. In this article, we briefly compiled the general aspects of Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery carrier system to enhance therapeutic effects of drug and the high level of patient compliance. Recently developed several vaccines might be shortly available as reported by WHO.

Download Full-text